{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-069317","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2022-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.403338+00:00","generated_at":"2026-06-25T03:25:19.971935+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rigel FORWARD Phase 3 trial of fostamatinib in wAIHA misses primary endpoint overall; positive regional signals seen","bullets":["Primary endpoint of durable hemoglobin response not met: fostamatinib 35.6% vs placebo 26.7% (p=0.398).","Post-hoc analysis: U.S./Canada/Australia/Western Europe showed significant benefit (36.0% vs 10.7%, p=0.03); Eastern Europe did not (35% vs 52.9%, p=0.304).","Safety profile consistent with prior data; most common AEs: diarrhea (26.7%), hypertension (24.4%), fatigue (15.6%).","Rigel plans further data analysis and discussion with FDA regarding regional differences.","71 of 90 patients (79%) enrolled in open-label extension study; data to be reported later."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-069317","json":"https://secwatch.observer/filing/0001104659-22-069317.json","markdown":"https://secwatch.observer/filing/0001104659-22-069317.md","text":"https://secwatch.observer/filing/0001104659-22-069317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922069317/0001104659-22-069317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922069317/tm2217976d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:25:19.971935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}